162 related articles for article (PubMed ID: 15586244)
1. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia.
Tsuchiya N; Wang L; Horikawa Y; Inoue T; Kakinuma H; Matsuura S; Sato K; Ogawa O; Kato T; Habuchi T
Int J Oncol; 2005 Jan; 26(1):225-31. PubMed ID: 15586244
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism.
Wang L; Habuchi T; Mitsumori K; Li Z; Kamoto T; Kinoshita H; Tsuchiya N; Sato K; Ohyama C; Nakamura A; Ogawa O; Kato T
Int J Cancer; 2003 Jan; 103(1):116-20. PubMed ID: 12455063
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer.
Wang L; Habuchi T; Tsuchiya N; Mitsumori K; Ohyama C; Sato K; Kinoshita H; Kamoto T; Nakamura A; Ogawa O; Kato T
Cancer Res; 2003 Aug; 63(15):4407-11. PubMed ID: 12907612
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic CA repeat length in insulin-like growth factor 1 and risk of breast cancer in Iranian women.
Javadi M; Hematti S; Tavassoli M
Med Oncol; 2012 Jun; 29(2):516-20. PubMed ID: 21484083
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA PCA3 gene promoter region is related to the risk of prostate cancer on Chinese males.
Zhou W; Tao Z; Wang Z; Hu W; Shen M; Zhou L; Wen Z; Yu Z; Wu X; Huang K; Hu Y; Lin X
Exp Mol Pathol; 2014 Dec; 97(3):550-3. PubMed ID: 25445501
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer.
Kumazawa T; Tsuchiya N; Wang L; Sato K; Kamoto T; Ogawa O; Nakamura A; Kato T; Habuchi T
Int J Cancer; 2004 May; 110(1):140-4. PubMed ID: 15054879
[TBL] [Abstract][Full Text] [Related]
8. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
Safarinejad MR; Shafiei N; Safarinejad S
Growth Horm IGF Res; 2011 Jun; 21(3):146-54. PubMed ID: 21536469
[TBL] [Abstract][Full Text] [Related]
9. Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population.
Kamoto T; Isogawa Y; Shimizu Y; Minamiguchi S; Kinoshita H; Kakehi Y; Mitsumori K; Yamamoto S; Habuchi T; Kato T; Ogawa O
Jpn J Clin Oncol; 2005 Mar; 35(3):158-61. PubMed ID: 15741307
[TBL] [Abstract][Full Text] [Related]
10. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer.
Friedrichsen DM; Hawley S; Shu J; Humphrey M; Sabacan L; Iwasaki L; Etzioni R; Ostrander EA; Stanford JL
Prostate; 2005 Sep; 65(1):44-51. PubMed ID: 15800934
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
12. Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men.
Han Z; Zhang L; Zhu R; Luo L; Zhu M; Fan L; Wang G
Medicine (Baltimore); 2017 Mar; 96(13):e6473. PubMed ID: 28353585
[TBL] [Abstract][Full Text] [Related]
13. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese.
Hamasaki T; Inatomi H; Katoh T; Ikuyama T; Matsumoto T
Urol Int; 2002; 68(4):226-31. PubMed ID: 12053022
[TBL] [Abstract][Full Text] [Related]
14. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
15. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
[TBL] [Abstract][Full Text] [Related]
18. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.
Tanaka Y; Sasaki M; Shiina H; Tokizane T; Deguchi M; Hirata H; Hinoda Y; Okayama N; Suehiro Y; Urakami S; Kawakami T; Kaneuchi M; Pookot D; Igawa M; Okuyama A; Ishii N; Dahiya R
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):238-44. PubMed ID: 16492910
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
[TBL] [Abstract][Full Text] [Related]
20. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
Zambra FM; Biolchi V; Brum IS; Chies JA
Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
